Benzinga | Oct 12, 2021 08:32AM EDT

Morgan Stanley Maintains Overweight on Legend Biotech, Raises Price Target to $51

Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and raises the price target from $50 to $51.